P8RI |
| رقم الكتالوجGC63477 |
P8RI (D-P8RI) عبارة عن ببتيد مقلد حيوي لـ CD31 ومنبه CD31
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2147724-76-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway[1][2].
P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases[1].
P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury[3].
[1]. Diaz-Rodriguez S, et al. Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo. Eur Heart J. 2021;42(18):1760-1769. [2]. Sannier A, et al. A CD31-Derived Peptide Prevents the Development of Antibody-Mediated Lesions in a Rat Model of Aortic Allograft. Transplant Proc. 2021;53(2):746-749. [3]. Andreata F, et al. Macrophage CD31 Signaling in Dissecting Aortic Aneurysm. J Am Coll Cardiol. 2018;72(1):45-57.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *